Skip to main content
SpringerLink
Log in

FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

The association among plasma trimethylamine-N-oxide (TMAO), FMO3 polymorphisms, and chronic heart failure (CHF) remains to be elucidated. TMAO is a microbiota-dependent metabolite from dietary choline and carnitine. A prospective study was performed including 955 consecutively diagnosed CHF patients with reduced ejection fraction, with the longest follow-up of 7 years. The concentrations of plasma TMAO and its precursors, namely, choline and carnitine, were determined by liquid chromatography-mass spectrometry, and the FMO3 E158K polymorphisms (rs2266782) were genotyped. The top tertile of plasma TMAO was associated with a significant increment in hazard ratio (HR) for the composite outcome of cardiovascular death or heart transplantation (HR = 1.47, 95% CI = 1.13–1.91, P = 0.004) compared with the lowest tertile. After adjustments of the potential confounders, higher TMAO could still be used to predict the risk of the primary endpoint (adjusted HR = 1.33, 95% CI = 1.01–1.74, P = 0.039). This result was also obtained after further adjustment for carnitine (adjusted HR = 1.33, 95% CI = 1.01–1.74, P = 0.039). The FMO3 rs2266782 polymorphism was associated with the plasma TMAO concentrations in our cohort, and lower TMAO levels were found in the AA-genotype. Thus, higher plasma TMAO levels indicated increased risk of the composite outcome of cardiovascular death or heart transplantation independent of potential confounders, and the FMO3 AA-genotype in rs2266782 was related to lower plasma TMAO levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, Daviglus ML, Lloyd-Jones DM. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol 2013; 61(14): 1510–1517

    Article  Google Scholar 

  2. Sato N. Epidemiology of heart failure in Asia. Heart Fail Clin 2015; 11(4): 573–579

    Article  Google Scholar 

  3. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472(7341): 57–63

    Article  CAS  Google Scholar 

  4. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368(17): 1575–1584

    Article  CAS  Google Scholar 

  5. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen SL. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014; 64(18): 1908–1914

    Article  CAS  Google Scholar 

  6. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y, Hazen SL. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J 2014; 35(14): 904–910

    Article  CAS  Google Scholar 

  7. Senthong V, Li XS, Hudec T, Coughlin J, Wu Y, Levison B, Wang Z, Hazen SL, Tang WH. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J Am Coll Cardiol 2016; 67(22): 2620–2628

    Article  CAS  Google Scholar 

  8. Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L, Windecker S, Rodondi N, Nanchen D, Muller O, Miranda MX, Matter CM, Wu Y, Li L, Wang Z, Alamri HS, Gogonea V, Chung YM, Tang WH, Hazen SL, Lüscher TF. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J 2017; 38(11): 814–824

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 2013; 17(1): 49–60

    Article  CAS  Google Scholar 

  10. Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, Marshall S, McDaniel A, Schugar RC, Wang Z, Sacks J, Rong X, Vallim TA, Chou J, Ivanova PT, Myers DS, Brown HA, Lee RG, Crooke RM, Graham MJ, Liu X, Parini P, Tontonoz P, Lusis AJ, Hazen SL, Temel RE, Brown JM. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep 2015; 10(3): 326–338

    Article  CAS  Google Scholar 

  11. Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, Brown AL, Gromovsky AD, Heine M, Chatterjee A, Li L, Li XS, Wang Z, Willard B, Meng Y, Kim H, Che N, Pan C, Lee RG, Crooke RM, Graham MJ, Morton RE, Langefeld CD, Das SK, Rudel LL, Zein N, McCullough AJ, Dasarathy S, Tang WHW, Erokwu BO, Flask CA, Laakso M, Civelek M, Naga Prasad SV, Heeren J, Lusis AJ, Hazen SL, Brown JM. The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue. Cell Rep 2017; 20(1): 279

    Article  CAS  Google Scholar 

  12. Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, Hines RN. Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol Pharmacol 2005; 68(2): 383–392

    Article  CAS  Google Scholar 

  13. Türkanoğlu Özçelik A, Can Demirdöğen B, Demirkaya S, Adali O. Flavin containing monooxygenase 3 genetic polymorphisms Glu158Lys and Glu308Gly and their relation to ischemic stroke. Gene 2013; 521(1): 116–121

    Article  Google Scholar 

  14. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16): e147–e239

    Article  Google Scholar 

  15. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19(5): 576–585

    Article  CAS  Google Scholar 

  16. Zhu Y, Jameson E, Crosatti M, Schäfer H, Rajakumar K, Bugg TD, Chen Y. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc Natl Acad Sci USA 2014; 111(11): 4268–4273

    Article  CAS  Google Scholar 

  17. Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, Org E, Wu Y, Li L, Smith JD, Tang WHW, DiDonato JA, Lusis AJ, Hazen SL. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab 2014; 20 (5): 799–812

    Article  CAS  Google Scholar 

  18. Cho CE, Caudill MA. Trimethylamine-N-oxide: friend, foe, or simply caught in the cross-fire? Trends Endocrinol Metab 2017; 28 (2): 121–130

    Article  CAS  Google Scholar 

  19. Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 2016; 27 (1): 305–313

    Article  CAS  Google Scholar 

  20. Shafi T, Powe NR, Meyer TW, Hwang S, Hai X, Melamed ML, Banerjee T, Coresh J, Hostetter TH. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients. J Am Soc Nephrol 2017; 28(1): 321–331

    Article  CAS  Google Scholar 

  21. Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ Res 2014; 114(1): 157–170

    Article  CAS  Google Scholar 

  22. Kathirvel E, Morgan K, Nandgiri G, Sandoval BC, Caudill MA, Bottiglieri T, French SW, Morgan TR. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol 2010; 299(5): G1068–G1077

    Article  CAS  Google Scholar 

  23. Wang LJ, Zhang HW, Zhou JY, Liu Y, Yang Y, Chen XL, Zhu CH, Zheng RD, Ling WH, Zhu HL. Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet. J Nutr Biochem 2014; 25(3): 329–336

    Article  Google Scholar 

  24. Lim GB. Gut flora—pathogenic role in chronic heart failure. Nat Rev Cardiol 2016; 13(2): 61

    Article  Google Scholar 

  25. Tang WH. We are not alone: understanding the contributions of intestinal microbial communities and the congested gut in heart failure. JACC Heart Fail 2016; 4(3): 228–229

    Article  Google Scholar 

  26. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, Verri M, Dioguardi F. Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail 2016; 4(3): 220–227

    Article  Google Scholar 

  27. Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, Qi H, Wu J, Pan C, Brown JM, Vallim T, Bennett BJ, Graham M, Hazen SL, Lusis AJ. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 2015; 56(1): 22–37

    Article  CAS  Google Scholar 

  28. Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, Croce KJ, Esquejo RM, Clish CB, Morbid Obesity Study Group; Vicent D, Biddinger SB. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun 2015; 6(1): 6498

    Article  CAS  Google Scholar 

  29. Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol 2013; 85(11): 1588–1593

    Article  CAS  Google Scholar 

  30. Lambert DM, Mamer OA, Akerman BR, Choinière L, Gaudet D, Hamet P, Treacy EP. In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol Genet Metab 2001; 73(3): 224–229

    Article  CAS  Google Scholar 

  31. Morandi A, Zusi C, Corradi M, Olivieri F, Piona C, Fornari E, Maffeis C. Minor diplotypes of FMO3 might protect children and adolescents from obesity and insulin resistance. Int J Obes 2018; 42 (6): 1243–1248

    Article  CAS  Google Scholar 

  32. Shan Z, Sun T, Huang H, Chen S, Chen L, Luo C, Yang W, Yang X, Yao P, Cheng J, Hu FB, Liu L. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. Am J Clin Nutr 2017; 106(3): 888–894

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by National Key R&D Program of China (Nos. 2017YFC0909400 and 2017YFC1307700), Projects from National Natural Science Foundation of China (Nos. 81630010, 91639108, 81770272, 81873506, 82070235, and 81790624), the Beijing Municipal Natural Science Foundation (No. 7191013), China Postdoctoral Science Foundation (No. 2020M680261), National Postdoctoral Program for Innovative Talents (No. BX20200022) and Integrated Innovative Team for Human Disease Program of Tongji Medical College, HUST (No. 2015ZDTD044).

Author information

Author notes

  1. Haoran Wei and Mingming Zhao equally contributed to this work.

Authors and Affiliations

  1. Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, 430030, China

    Haoran Wei, Man Huang, Chenze Li, Ting Yu, Xiaoqing Shen, Li Ni, Chunxia Zhao & Dao Wen Wang

  2. Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, 100191, China

    Mingming Zhao & Erdan Dong

  3. The Institute of Cardiovascular Sciences, Peking University; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, 100191, China

    Mingming Zhao, Jianing Gao, Qi Zhang, Liang Ji, Erdan Dong & Lemin Zheng

  4. Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

    Chenze Li

  5. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA

    Zeneng Wang

Authors
  1. Haoran Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingming Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Man Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chenze Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jianing Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ting Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaoqing Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Liang Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Li Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chunxia Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zeneng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Erdan Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Lemin Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Dao Wen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lemin Zheng or Dao Wen Wang.

Additional information

Compliance with ethics guidelines

Haoran Wei, Mingming Zhao, Man Huang, Chenze Li, Jianing Gao, Ting Yu, Qi Zhang, Xiaoqing Shen, Liang Ji, Li Ni, Chunxia Zhao, Zeneng Wang, Erdan Dong, Lemin Zheng, and Dao Wen Wang declare that they have no conflict of interest. This study was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. This research was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. Written informed consent was obtained from all individuals at admission.

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, H., Zhao, M., Huang, M. et al. FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population. Front. Med. 16, 295–305 (2022). https://doi.org/10.1007/s11684-021-0857-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-021-0857-2

Keywords

Search

Navigation